Comparative Pharmacology
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus LODINE.
FENOPROFEN CALCIUM vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Oral: 300-600 mg every 6-8 hours as needed; maximum 3200 mg/day.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours; may be prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug; <2% excreted in feces.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category C
Category C
NSAID
NSAID